New pay-for-delay deals ripe for investigation, former US FTC officials say
Branded drug manufacturers and their generic drug competitors have developed increasingly sophisticated ways to keep prices high through anticompetitive agreements, and the US Federal Trade Commission should open investigations into practices...To view the full article, register now.
Already a subscriber? Click here to view full article